James Quigley
Stock Analyst at Morgan Stanley
(0.36)
# 3,652
Out of 4,667 analysts
20
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $45 → $49 | $44.05 | +11.24% | 5 | Nov 6, 2024 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $103.09 | +17.37% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.60 | +22.09% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $25.64 | +56.01% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $5.30 | +201.89% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $45 → $49
Current: $44.05
Upside: +11.24%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $103.09
Upside: +17.37%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.60
Upside: +22.09%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $25.64
Upside: +56.01%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $5.30
Upside: +201.89%